3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
32
Gastrointestinal
17
Dermatologic
15
Thoracic
12
Gynecologic
9
Genitourinary
9
Breast
4
Other solid neoplasm
2
Lymphoid
2
Sarcoma
1
Other
1
NET
1
Endocrine
1
Conditions
Obesity
298
Mucositis
116
Neoplasms
108
Breast Neoplasms
87
Overweight
80
Sexual Dysfunction, Physiological
74
Polycystic Ovary Syndrome
71
Dyspnea
48
Motor Activity
46
Constipation
45
Head and Neck Neoplasms
42
Weight Loss
36
Prostatic Neoplasms
32
Pain
29
Stomatitis
26
Endometrial Neoplasms
23
Opioid-Induced Constipation
22
Multiple Endocrine Neoplasia Type 1
20
Diabetes Mellitus
20
Lung Neoplasms
18
Colorectal Neoplasms
17
Precursor Cell Lymphoblastic Leukemia-Lymphoma
16
Sexual Dysfunctions, Psychological
15
Depression
15
Cardiovascular Diseases
15
Anxiety Disorders
15
Sedentary Behavior
13
Insulin Resistance
13
Infertility
13
Cancer-related Fatigue
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasms, Squamous Cell
×
Other
×
Clear all
NCT01283906
2013-09-12
MuGard
Access Pharmaceuticals, Inc.
Phase 4
Completed
120 enrolled